The team also evaluated and compared the diagnostic performance of MIC-1 with CA19.
The sensitivity of serum MIC-1 for the detection of PDAC was significantly higher compared with that of CA19.
Additionally, data from receiver operating characteristic (ROC) curve analysis demonstrated that serum MIC-1 had a superior performance to CA19.
Randall Brand: Excluding cystic neoplasms of the pancreas, the only commercially available biomarker used for PC is CA19.
The European Group on Tumor Markers (EGTM) considers CA19.
The National Academy of Clinical Biochemistry and the EGTM recommend that serial determinations of CA19.